 Anne Lynch
Concepts (319)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 13 | 2024 | 141 | 5.960 |
Why?
| | Macular Degeneration | 12 | 2023 | 159 | 3.950 |
Why?
| | Geographic Atrophy | 10 | 2025 | 69 | 2.600 |
Why?
| | Birth Weight | 11 | 2024 | 506 | 2.260 |
Why?
| | Complement Factor B | 7 | 2022 | 109 | 2.260 |
Why?
| | Visual Acuity | 17 | 2024 | 327 | 1.910 |
Why?
| | Wet Macular Degeneration | 6 | 2025 | 46 | 1.860 |
Why?
| | Pre-Eclampsia | 8 | 2024 | 188 | 1.690 |
Why?
| | Neonatal Screening | 5 | 2022 | 163 | 1.690 |
Why?
| | Cataract | 12 | 2024 | 209 | 1.610 |
Why?
| | Retinal Drusen | 3 | 2024 | 31 | 1.600 |
Why?
| | Gestational Age | 16 | 2024 | 876 | 1.590 |
Why?
| | Premature Birth | 5 | 2017 | 317 | 1.440 |
Why?
| | Complement Activation | 6 | 2022 | 384 | 1.320 |
Why?
| | Phacoemulsification | 8 | 2023 | 116 | 1.200 |
Why?
| | Infant, Premature | 7 | 2024 | 542 | 1.120 |
Why?
| | Registries | 9 | 2025 | 1899 | 1.030 |
Why?
| | Complement C3a | 2 | 2019 | 41 | 1.010 |
Why?
| | Tomography, Optical Coherence | 7 | 2025 | 186 | 1.000 |
Why?
| | Cataract Extraction | 7 | 2024 | 97 | 0.920 |
Why?
| | Fluorescein Angiography | 6 | 2025 | 143 | 0.890 |
Why?
| | Infant, Newborn | 16 | 2024 | 5756 | 0.890 |
Why?
| | Diseases in Twins | 1 | 2024 | 176 | 0.850 |
Why?
| | Diabetic Retinopathy | 5 | 2023 | 178 | 0.840 |
Why?
| | Twins | 1 | 2024 | 249 | 0.820 |
Why?
| | Retrospective Studies | 37 | 2024 | 14522 | 0.800 |
Why?
| | Risk Factors | 22 | 2024 | 9786 | 0.790 |
Why?
| | Fetal Membranes, Premature Rupture | 3 | 2017 | 36 | 0.740 |
Why?
| | Pregnancy | 25 | 2024 | 6417 | 0.740 |
Why?
| | Weight Gain | 4 | 2019 | 509 | 0.700 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 113 | 0.680 |
Why?
| | Infant, Low Birth Weight | 2 | 2017 | 135 | 0.650 |
Why?
| | Pregnancy Outcome | 7 | 2015 | 391 | 0.650 |
Why?
| | Cohort Studies | 11 | 2024 | 5426 | 0.630 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 37 | 0.630 |
Why?
| | Female | 66 | 2025 | 68734 | 0.630 |
Why?
| | Humans | 87 | 2025 | 129625 | 0.630 |
Why?
| | Internet | 1 | 2023 | 618 | 0.600 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 55 | 0.600 |
Why?
| | Biomarkers | 11 | 2025 | 3968 | 0.600 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2024 | 379 | 0.590 |
Why?
| | Algorithms | 6 | 2018 | 1616 | 0.570 |
Why?
| | Labor, Induced | 2 | 2017 | 30 | 0.570 |
Why?
| | Colorado | 12 | 2025 | 4404 | 0.560 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 179 | 0.560 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 38 | 0.540 |
Why?
| | Retinal Detachment | 3 | 2023 | 58 | 0.530 |
Why?
| | Labor, Obstetric | 1 | 2017 | 58 | 0.530 |
Why?
| | Blood Proteins | 2 | 2015 | 244 | 0.520 |
Why?
| | Intraocular Pressure | 5 | 2024 | 299 | 0.510 |
Why?
| | Pregnancy Trimester, First | 2 | 2015 | 137 | 0.490 |
Why?
| | Refraction, Ocular | 4 | 2024 | 36 | 0.480 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 306 | 0.460 |
Why?
| | Infant, Very Low Birth Weight | 4 | 2019 | 67 | 0.440 |
Why?
| | Infant | 12 | 2022 | 8995 | 0.430 |
Why?
| | Multimodal Imaging | 2 | 2025 | 110 | 0.430 |
Why?
| | Placenta | 2 | 2018 | 723 | 0.430 |
Why?
| | Inflammation | 4 | 2023 | 2750 | 0.420 |
Why?
| | Intraoperative Complications | 4 | 2022 | 129 | 0.420 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 19 | 0.420 |
Why?
| | Male | 41 | 2025 | 63670 | 0.410 |
Why?
| | Keratomileusis, Laser In Situ | 2 | 2024 | 22 | 0.410 |
Why?
| | Aged | 24 | 2025 | 22061 | 0.410 |
Why?
| | Myopia | 3 | 2024 | 47 | 0.410 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2012 | 146 | 0.400 |
Why?
| | Research Design | 1 | 2019 | 1045 | 0.400 |
Why?
| | Aged, 80 and over | 14 | 2025 | 7052 | 0.380 |
Why?
| | Vitrectomy | 3 | 2021 | 66 | 0.380 |
Why?
| | Logistic Models | 9 | 2024 | 1986 | 0.380 |
Why?
| | Cesarean Section | 3 | 2011 | 181 | 0.380 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 0.370 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 59 | 0.370 |
Why?
| | Body Mass Index | 4 | 2014 | 2274 | 0.360 |
Why?
| | Odds Ratio | 5 | 2019 | 1019 | 0.360 |
Why?
| | Retinal Diseases | 2 | 2023 | 87 | 0.360 |
Why?
| | Pregnancy Complications | 3 | 2010 | 493 | 0.350 |
Why?
| | Follow-Up Studies | 12 | 2025 | 4894 | 0.350 |
Why?
| | Prospective Studies | 15 | 2025 | 7135 | 0.340 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2012 | 368 | 0.340 |
Why?
| | Complement Activating Enzymes | 1 | 2010 | 3 | 0.340 |
Why?
| | Pregnant Women | 1 | 2011 | 114 | 0.330 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 71 | 0.320 |
Why?
| | Influenza Vaccines | 2 | 2012 | 532 | 0.320 |
Why?
| | Immunologic Factors | 2 | 2022 | 230 | 0.300 |
Why?
| | Obesity | 3 | 2014 | 2882 | 0.290 |
Why?
| | Influenza, Human | 2 | 2012 | 601 | 0.290 |
Why?
| | Complement Pathway, Alternative | 2 | 2013 | 120 | 0.290 |
Why?
| | Adult | 24 | 2024 | 35599 | 0.280 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 381 | 0.280 |
Why?
| | Antibodies, Antiphospholipid | 3 | 1999 | 26 | 0.280 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1843 | 0.280 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 834 | 0.280 |
Why?
| | Lenses, Intraocular | 3 | 2022 | 43 | 0.280 |
Why?
| | Antigens, CD | 1 | 2010 | 487 | 0.270 |
Why?
| | Lasers, Excimer | 2 | 2024 | 29 | 0.270 |
Why?
| | Case-Control Studies | 7 | 2022 | 3378 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.240 |
Why?
| | Incidence | 4 | 2022 | 2641 | 0.240 |
Why?
| | Glaucoma | 2 | 2018 | 221 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2011 | 1280 | 0.230 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1001 | 0.220 |
Why?
| | Postoperative Complications | 5 | 2023 | 2477 | 0.220 |
Why?
| | Choroid | 1 | 2024 | 62 | 0.220 |
Why?
| | Disease Progression | 5 | 2025 | 2627 | 0.210 |
Why?
| | Membrane Proteins | 1 | 2010 | 1125 | 0.210 |
Why?
| | Vitreous Body | 2 | 2022 | 109 | 0.210 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 68 | 0.210 |
Why?
| | Methylprednisolone | 1 | 2023 | 83 | 0.200 |
Why?
| | Optic Neuritis | 1 | 2023 | 40 | 0.200 |
Why?
| | Middle Aged | 19 | 2025 | 31136 | 0.200 |
Why?
| | Vision, Low | 1 | 2022 | 16 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 219 | 0.200 |
Why?
| | Vaccination | 1 | 2011 | 1347 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1499 | 0.190 |
Why?
| | Retinal Perforations | 1 | 2022 | 13 | 0.190 |
Why?
| | Proteomics | 2 | 2020 | 1055 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.180 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 101 | 0.180 |
Why?
| | Capsule Opacification | 1 | 2021 | 22 | 0.180 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.180 |
Why?
| | Complement System Proteins | 2 | 2022 | 318 | 0.180 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.180 |
Why?
| | Corneal Transplantation | 1 | 2020 | 13 | 0.180 |
Why?
| | Trabeculectomy | 2 | 2018 | 72 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Abortion, Spontaneous | 2 | 1999 | 100 | 0.170 |
Why?
| | Optics and Photonics | 1 | 2020 | 42 | 0.170 |
Why?
| | Risk Assessment | 3 | 2019 | 3262 | 0.170 |
Why?
| | Quality of Life | 5 | 2023 | 2688 | 0.170 |
Why?
| | Dementia | 1 | 2023 | 225 | 0.170 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 38 | 0.170 |
Why?
| | Strabismus | 1 | 2020 | 28 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.160 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 57 | 0.160 |
Why?
| | Macula Lutea | 1 | 2019 | 21 | 0.160 |
Why?
| | Hepatitis C | 1 | 2022 | 243 | 0.160 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 25 | 0.160 |
Why?
| | Laser Therapy | 1 | 2021 | 129 | 0.160 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 5415 | 0.160 |
Why?
| | United States | 8 | 2020 | 13871 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2020 | 176 | 0.160 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.160 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 319 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 137 | 0.150 |
Why?
| | Pilocarpine | 1 | 2018 | 15 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 18 | 0.150 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1999 | 78 | 0.150 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2442 | 0.150 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 75 | 0.150 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.150 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 79 | 0.140 |
Why?
| | Ocular Hypertension | 1 | 2018 | 67 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 318 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 482 | 0.140 |
Why?
| | Laser Coagulation | 1 | 2017 | 57 | 0.140 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 17 | 0.130 |
Why?
| | Glycoproteins | 1 | 1999 | 338 | 0.130 |
Why?
| | Parity | 1 | 2017 | 120 | 0.130 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 102 | 0.130 |
Why?
| | Automobile Driving | 1 | 2018 | 140 | 0.130 |
Why?
| | Tonometry, Ocular | 3 | 2024 | 89 | 0.130 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 20 | 0.130 |
Why?
| | Time Factors | 4 | 2021 | 6555 | 0.130 |
Why?
| | Fetus | 2 | 2018 | 774 | 0.130 |
Why?
| | Young Adult | 8 | 2019 | 12455 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 642 | 0.120 |
Why?
| | Risk | 1 | 2018 | 855 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2739 | 0.120 |
Why?
| | Time-to-Pregnancy | 1 | 2015 | 5 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5075 | 0.120 |
Why?
| | Fundus Oculi | 2 | 2025 | 61 | 0.110 |
Why?
| | Proteins | 1 | 2020 | 944 | 0.110 |
Why?
| | Phenotype | 2 | 2022 | 3075 | 0.110 |
Why?
| | Mothers | 2 | 2018 | 731 | 0.110 |
Why?
| | Self Report | 1 | 2018 | 799 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 226 | 0.110 |
Why?
| | Obstetric Labor, Premature | 1 | 2013 | 35 | 0.110 |
Why?
| | Cervical Ripening | 1 | 2013 | 9 | 0.100 |
Why?
| | Sulfonamides | 1 | 2016 | 497 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2013 | 49 | 0.100 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 33 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2024 | 10219 | 0.100 |
Why?
| | Models, Statistical | 1 | 2016 | 625 | 0.100 |
Why?
| | Pulmonary Fibrosis | 2 | 2008 | 385 | 0.090 |
Why?
| | Aspirin | 1 | 2015 | 380 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 15 | 0.090 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 29 | 0.090 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 85 | 0.090 |
Why?
| | Fetal Blood | 1 | 2013 | 317 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2015 | 443 | 0.090 |
Why?
| | Autoantibodies | 1 | 1999 | 1468 | 0.090 |
Why?
| | Endoglin | 1 | 2010 | 19 | 0.080 |
Why?
| | Adiposity | 1 | 2014 | 504 | 0.080 |
Why?
| | Hypertension | 1 | 1999 | 1243 | 0.080 |
Why?
| | Cesarean Section, Repeat | 1 | 2009 | 11 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 530 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2009 | 40 | 0.080 |
Why?
| | Postoperative Period | 2 | 2020 | 330 | 0.080 |
Why?
| | Placental Insufficiency | 1 | 2010 | 112 | 0.080 |
Why?
| | Child | 4 | 2022 | 20884 | 0.080 |
Why?
| | Models, Biological | 1 | 2016 | 1724 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 475 | 0.070 |
Why?
| | Seasons | 1 | 2011 | 494 | 0.070 |
Why?
| | Pregnancy Trimester, Third | 1 | 2008 | 109 | 0.070 |
Why?
| | Health Status Disparities | 1 | 2011 | 256 | 0.070 |
Why?
| | Heart Rate | 1 | 2012 | 802 | 0.070 |
Why?
| | Elective Surgical Procedures | 1 | 2009 | 164 | 0.070 |
Why?
| | ROC Curve | 2 | 2019 | 503 | 0.070 |
Why?
| | Resuscitation | 1 | 2009 | 237 | 0.070 |
Why?
| | Patient Compliance | 1 | 2011 | 565 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3628 | 0.060 |
Why?
| | Glyburide | 1 | 2006 | 35 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2008 | 2512 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1947 | 0.060 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1221 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1736 | 0.060 |
Why?
| | Ultrasonography, Doppler | 1 | 2005 | 118 | 0.060 |
Why?
| | Urban Health | 1 | 2004 | 79 | 0.060 |
Why?
| | Papanicolaou Test | 1 | 2004 | 42 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2004 | 55 | 0.060 |
Why?
| | Fetal Growth Retardation | 2 | 2012 | 550 | 0.060 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2004 | 17 | 0.060 |
Why?
| | Refractive Errors | 1 | 2024 | 18 | 0.060 |
Why?
| | Uterus | 1 | 2005 | 207 | 0.060 |
Why?
| | Prevalence | 2 | 2024 | 2564 | 0.060 |
Why?
| | Hospitals, County | 1 | 2023 | 10 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2004 | 64 | 0.050 |
Why?
| | Length of Stay | 1 | 2009 | 1122 | 0.050 |
Why?
| | Double-Blind Method | 4 | 2015 | 1875 | 0.050 |
Why?
| | Retinal Pigment Epithelium | 1 | 2024 | 70 | 0.050 |
Why?
| | Neuroprotection | 1 | 2023 | 39 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1501 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 133 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 212 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1491 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 33 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 153 | 0.050 |
Why?
| | Diabetes, Gestational | 1 | 2006 | 308 | 0.050 |
Why?
| | Cornea | 1 | 2022 | 128 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 103 | 0.050 |
Why?
| | Vision Disorders | 1 | 2022 | 135 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 163 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 53 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 239 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 55 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 11 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 18 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 56 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 62 | 0.040 |
Why?
| | Growth Charts | 1 | 2019 | 14 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 91 | 0.040 |
Why?
| | Canada | 1 | 2020 | 350 | 0.040 |
Why?
| | Adolescent | 5 | 2020 | 20412 | 0.040 |
Why?
| | HIV | 1 | 2020 | 227 | 0.040 |
Why?
| | beta 2-Glycoprotein I | 1 | 1999 | 4 | 0.040 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1999 | 8 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 38 | 0.040 |
Why?
| | Pulmonary Gas Exchange | 1 | 1999 | 121 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 204 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 304 | 0.040 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 76 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 1999 | 88 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 761 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| | Child, Preschool | 3 | 2022 | 10490 | 0.040 |
Why?
| | Confidence Intervals | 1 | 1999 | 317 | 0.040 |
Why?
| | Family | 1 | 2022 | 646 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2720 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 234 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 1999 | 276 | 0.030 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 241 | 0.030 |
Why?
| | North America | 1 | 2018 | 292 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 730 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 736 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 514 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 876 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 688 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 313 | 0.030 |
Why?
| | Interferon-beta | 2 | 2008 | 89 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 1999 | 851 | 0.030 |
Why?
| | Plethysmography | 1 | 2014 | 106 | 0.030 |
Why?
| | Apgar Score | 1 | 1994 | 16 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2008 | 581 | 0.030 |
Why?
| | Nitric Oxide | 1 | 1999 | 895 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1936 | 0.030 |
Why?
| | Mice | 1 | 2010 | 16961 | 0.030 |
Why?
| | Linear Models | 1 | 2014 | 819 | 0.020 |
Why?
| | Treatment Failure | 2 | 2006 | 339 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 446 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2012 | 162 | 0.020 |
Why?
| | Body Composition | 1 | 2014 | 649 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2014 | 591 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1213 | 0.020 |
Why?
| | Animals | 1 | 2010 | 35391 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2012 | 602 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 515 | 0.020 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 62 | 0.020 |
Why?
| | Rheology | 1 | 2005 | 90 | 0.010 |
Why?
| | Chicago | 1 | 2004 | 57 | 0.010 |
Why?
| | Survival Analysis | 1 | 2008 | 1269 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1198 | 0.010 |
Why?
| | Ethinyl Estradiol | 1 | 2004 | 17 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2004 | 37 | 0.010 |
Why?
| | Desogestrel | 1 | 2004 | 45 | 0.010 |
Why?
| | Ultrasonography, Prenatal | 1 | 2005 | 274 | 0.010 |
Why?
| | Menstrual Cycle | 1 | 2004 | 121 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 230 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 767 | 0.010 |
Why?
| | Women's Health | 1 | 2004 | 364 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 997 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1999 | 667 | 0.010 |
Why?
| | Oxygen | 1 | 1999 | 915 | 0.010 |
Why?
| | Hypoxia | 1 | 1999 | 1084 | 0.010 |
Why?
|
|
Lynch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|